Sicart Associates LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 101,310 shares of the biopharmaceutical company's stock after selling 4,620 shares during the period. Gilead Sciences makes up approximately 3.9% of Sicart Associates LLC's holdings, making the stock its 4th biggest holding. Sicart Associates LLC's holdings in Gilead Sciences were worth $11,352,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC boosted its stake in Gilead Sciences by 158.8% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 216 shares during the period. Whipplewood Advisors LLC bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $35,000. Synergy Investment Management LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $40,000. Lee Danner & Bass Inc. bought a new position in shares of Gilead Sciences during the fourth quarter worth about $41,000. Finally, Investment Research & Advisory Group Inc. raised its position in Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 100 shares during the last quarter. 83.67% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
GILD has been the subject of a number of recent research reports. Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target for the company. Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Bank of America lifted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, Morgan Stanley raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $110.55.
Check Out Our Latest Report on GILD
Insider Buying and Selling
In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the transaction, the chief executive officer now owns 620,268 shares in the company, valued at $68,489,992.56. This represents a 1.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider now directly owns 121,152 shares in the company, valued at $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,500 shares of company stock valued at $5,236,245. Insiders own 0.27% of the company's stock.
Gilead Sciences Price Performance
NASDAQ:GILD opened at $110.67 on Friday. The company has a market cap of $137.67 billion, a P/E ratio of 23.30, a P/E/G ratio of 0.72 and a beta of 0.29. The firm's fifty day moving average price is $106.39 and its two-hundred day moving average price is $103.35. Gilead Sciences, Inc. has a one year low of $66.01 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences's quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.32) EPS. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were paid a dividend of $0.79 per share. The ex-dividend date was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.86%. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
